In the BioHarmony Drug Report Database

"Preview" Icon

Dostarlimab

Jemperli (dostarlimab) is an antibody pharmaceutical. Dostarlimab was first approved as Jemperli on 2021-04-21. It has been approved in Europe to treat endometrial neoplasms. It is known to target programmed cell death protein 1.

 

Trade Name

 

Jemperli
 

Common Name

 

dostarlimab
 

ChEMBL ID

 

CHEMBL4298124
 

Indication

 

endometrial neoplasms
 

Drug Class

 

Monoclonal antibodies: immunomodulating

Image (chem structure or protein)

Dostarlimab structure rendering